Valo Health, Inc. announced a strategic collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to advance therapeutic discovery in Parkinson's disease and related disorders. The partnership will leverage Valo's AI-enabled human causal biology platform to identify and validate novel disease targets and its closed loop discovery platform to rapidly generate preclinical compounds. The partnership includes upfront and potential milestone payments totaling up to over 3 billion dollars, as well as royalties and R&D funding.
Valo's human causal biology platform harnesses unique access to more than 17 million de-identified patient records--some spanning 20 to 30 years--and biobank samples, combined with advanced AI, to uncover disease patterns and pinpoint potential targets for therapeutic intervention. In neurological conditions specifically, this robust human data has enabled Valo to identify distinct patient phenotypes across the disease spectrum, each defined by unique clinical characteristics that influence progression and reveal areas of unmet need. Using human-validated targets as a starting point, Valo's closed loop chemistry platform is designed to rapidly develop and optimize small molecules that are engineered to engage these novel disease targets.
Valo has a dual approach to therapeutic discovery: advancing its own pipeline of assets across multiple disease areas, while partnering with pharmaceutical companies like Merck KGaA,D Germany to accelerate pre-clinical R&D. By integrating Valo's early R&D capabilities with the clinical development expertise and scale of its pharmaceutical partners, promising drug candidates can be advanced more efficiently and delivered to patients, faster.
